Feng Ziren, Zhang Xinning, Wang Pan, Hu Qinglan, Lin Jinduan
Department of Laboratory Medicine.
Unit of Gynecologic, Affiliated Qingyuan Hospital, Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, Guangdong, People's Republic of China.
Ann Med Surg (Lond). 2024 May 6;86(8):4788-4792. doi: 10.1097/MS9.0000000000002135. eCollection 2024 Aug.
Ovary dysgerminoma is one of the most good prognosis malignant tumor, which has a 5-year overall survival rate exceeding to 90%. Generally, the incidence of ovarian dysgerminoma (OD) is relatively low, accounting for ~0.6% of all ovarian tumors. Usually, it mainly occurs in very young women, about 85% of patients under 30 years old and is rare in middle-aged especially in elderly ones. This ovary dysgerminoma case report presents a 58-year-old menopausal postmenopausal woman which has a poor prognosis. Therefore, there may be differences between the elderly and young women in clinical characteristic that require separate management. This case reports a postmenopausal woman who was diagnosed with ovary dysgerminoma. After surgery, the patient was treated chemotherapy with bleomycin, etoposide, and cisplatin (BEP) according to the treatment guidelines. Unusually, the patient developed bone marrow suppression and lymph node metastasis in final. This report explored the clinical characteristic in postmenopausal woman dysgerminoma. Changes in lactate dehydrogenase (LDH) throughout the course of the disease are closely related to the progression. The patient had a disease progression when treated with the conventional treatment (BEP). The applicability of this treatment protocol to postmenopausal patients requires further research. Postmenopausal woman dysgerminoma is rare but rapid progress. Whether BEP is suitable for OD in middle-aged and elderly people remains to be further validated in the future. LDH may be a potential biomarker for monitoring the progression of OD in the elderly.
卵巢无性细胞瘤是预后最好的恶性肿瘤之一，其5年总生存率超过90%。一般来说，卵巢无性细胞瘤（OD）的发病率相对较低，约占所有卵巢肿瘤的0.6%。通常，它主要发生在非常年轻的女性中，约85%的患者年龄在30岁以下，在中年尤其是老年女性中较为罕见。本卵巢无性细胞瘤病例报告介绍了一名58岁绝经后女性，其预后较差。因此，老年女性和年轻女性在临床特征上可能存在差异，需要分别进行管理。本病例报告了一名绝经后女性被诊断为卵巢无性细胞瘤。手术后，患者根据治疗指南接受了博来霉素、依托泊苷和顺铂（BEP）化疗。不同寻常的是，患者最终出现了骨髓抑制和淋巴结转移。本报告探讨了绝经后女性无性细胞瘤的临床特征。疾病过程中乳酸脱氢酶（LDH）的变化与病情进展密切相关。患者接受常规治疗（BEP）时病情进展。该治疗方案对绝经后患者的适用性需要进一步研究。绝经后女性无性细胞瘤罕见但进展迅速。BEP是否适用于中老年卵巢无性细胞瘤患者，未来仍有待进一步验证。LDH可能是监测老年卵巢无性细胞瘤病情进展的潜在生物标志物。
